Cystic fibrosis is one of the existing hereditary diseases that causes a serious health problem for those who suffer from it, with an incidence of one for every 2,500 babies.
Therefore, to achieve a faster diagnosis of the disease, the Spanish company Genetadi Biotech has developed a new test to diagnose cystic fibrosis in newborns.
We must remember that childhood cystic fibrosis is a hereditary degenerative chronic disease that affects the pulmonary and digestive system of babies, causing the body to produce a mucous substance that clogs the body's channels, leading to inflammations and infections in the lungs, pancreas or liver.
As with a large part of childhood diseases, an early diagnosis is very important, as it will be essential to increase the life expectancy of babies.
The new test, commercially known as Neonatal One Plus, represents an advance in the diagnosis of the disease both in terms of time and money, since the diagnosis of the disease is made approximately in the first fifteen days of the baby's life, helping to start timely treatments more quickly.
The way that the test has to diagnose or not a childhood cystic fibrosis is through a DNA analysis through baby's saliva.
Until now, childhood cystic fibrosis is detected by the Sweat Test before the baby's first year of life, and if the test was positive, new tests should be performed using genetic techniques and the results took up to three months making the diagnosis an expensive and prolonged process over time.
It is very important that you highlight the speed of this new test to diagnose cystic fibrosis in newborns, since this reduces the time of distress of the parents while they receive the results of the tests performed.
